{"disease":{"id":"egfr-tki-sensitizing-mutation","name":"egfr tki sensitizing mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06521034","title":"First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Yongchang Zhang","has_results":false},{"nct_id":"NCT07298148","title":"Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}